Rho kinase inhibitors for glaucoma treatment - Review.

Journal Article (Review)

Glaucoma is a progressive optic neuropathy characterized by the loss of ganglion cells and their axons. A major risk factor for glaucomatous visual field loss is elevated intraocular pressure (IOP), and several studies have shown that lowering IOP reduces the risk of glaucomatous progression. Currently, an increasing number of researches involve Rho kinase inhibitors, which are a new pharmacological class of hypotensive agents specifically targeting the diseased trabecular outflow pathway. Rho kinase inhibitors reduce IOP by increasing aqueous humor drainage through the primary outflow pathway in the eye, which is known as the trabecular meshwork. In addition to improving the outflow facility of the trabecular meshwork, Rho kinase inhibitors also enhance retinal ganglion cell survival after ischemic injury and increase ocular blood flow.

Full Text

Duke Authors

Cited Authors

  • Germano, RAS; Finzi, S; Challa, P; Susanna Junior, R

Published Date

  • November 2015

Published In

Volume / Issue

  • 78 / 6

Start / End Page

  • 388 - 391

PubMed ID

  • 26677046

Electronic International Standard Serial Number (EISSN)

  • 1678-2925

International Standard Serial Number (ISSN)

  • 0004-2749

Digital Object Identifier (DOI)

  • 10.5935/0004-2749.20150103

Language

  • eng